Aarey Drugs Board Approves AGM, Recommends Secretarial & Statutory Auditors for 5-Year Terms
The decisions are part of regular corporate governance and compliance, such as setting the AGM date and recommending auditor appointments, which typically have a low direct impact on stock price or immediate business operations.
The announcement primarily details the outcomes of a board meeting, including the scheduling of the AGM and the recommendation for re-appointment of statutory auditors and appointment of secretarial auditors, which are standard corporate governance activities.
Aarey Drugs & Pharmaceuticals Limited announced the outcomes of its Board Meeting held on 3 September 2025, which included: * The Board approved the draft Board Report, its Annexure, and the Annual Report along with the notice for calling the 35th Annual General Meeting (AGM) for the Financial Year ended 31 March 2025. * The 35th AGM will be held on Monday, 29 September 2025, at 11:00 P.M. (IST) through Video Conferencing / Other Audio Visual Means. * The Board approved the Book Closure of Register of Members and Transfer Books and the Cut-off date for E-voting for the 35th AGM. * Mr. Virendra G. Bhatt, Practicing Company Secretary, was approved as the Scrutinizer for the E-voting to be conducted at the 35th AGM. * Based on the Audit Committee's recommendation and subject to shareholder approval at the AGM, the Board recommended the appointment of M/s. Ashika Shetty, Practicing Company Secretary (C.P. No. 27779), as Secretarial Auditors for a period of five years, from the financial year 2025-26 to 2029-30. * The Board recommended the re-appointment of M/s. Motilal & Associates, Chartered Accountants (ICAI FIRM Registration No.: 106584W), as Statutory Auditors for a second term of five years, from the financial year 2025-26 to 2029-30, subject to shareholder approval.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under corporate actions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.